CorMedix Inc. Q3 FY25 Results

Summary

CorMedix Inc. announced its financial results for the third quarter ended September 30, 2025. The company reported net revenue of $104.3 million and net income of $108.6 million, or $1.26 per diluted share. The results were driven primarily by net product sales and a one-time tax benefit of $59.7 million. CorMedix raised its full-year 2025 pro forma net revenue guidance to a range of $390 to $410 million and expects fully synergized pro forma adjusted EBITDA to be between $220 and $240 million.

Key Highlights

1. 1

   CorMedix reported net revenue of $104.3 million and pro forma net revenue of $130.8 million for the third quarter of 2025.

2. 2

   DefenCath sales contributed $88.8 million of net revenue in Q3 2025.

3. 3

   The company recognized net income of $108.6 million and adjusted EBITDA of $71.9 million in the third quarter of 2025.

4. 4

   Basic and Fully Diluted EPS were $1.42 and $1.26 per share, respectively, for Q3 2025.

5. 5

   Full-year 2025 pro forma net revenue guidance is raised to a range of $390 to $410 million.

6. 6

   Fourth quarter net revenue guidance is set to a range of $115 to $135 million.

7. 7

   Fully synergized pro forma adjusted EBITDA for 2025 is expected to be in the range of $220 – $240 million.